The estimated Net Worth of Therapeutics Corp Lung Biot... is at least $305 millió dollars as of 9 December 2019. Therapeutics Biot owns over 500,000 units of TransMedics stock worth over $295,276,444 and over the last 5 years Therapeutics sold TMDX stock worth over $9,375,000.
Therapeutics has made over 1 trades of the TransMedics stock since 2019, according to the Form 4 filled with the SEC. Most recently Therapeutics sold 500,000 units of TMDX stock worth $9,375,000 on 9 December 2019.
The largest trade Therapeutics's ever made was selling 500,000 units of TransMedics stock on 9 December 2019 worth over $9,375,000. On average, Therapeutics trades about 250,000 units every 0 days since 2019. As of 9 December 2019 Therapeutics still owns at least 2,053,240 units of TransMedics stock.
You can see the complete history of Therapeutics Biot stock trades at the bottom of the page.
Therapeutics's mailing address filed with the SEC is 1040 SPRING STREET1040 SPRING STREET, , SILVER SPRINGSILVER SPRING, MDMD, 2091020910.
Over the last 5 years, insiders at TransMedics have traded over $99,976,312 worth of TransMedics stock and bought 154,333 units worth $3,250,328 . The most active insiders traders include Edwin M Jr Kania, Waleed H Hassanein és James R Tobin. On average, TransMedics executives and independent directors trade stock every 10 days with the average trade being worth of $2,982,476. The most recent stock trade was executed by Tamer I Khayal on 3 September 2024, trading 2,960 units of TMDX stock currently worth $98,065.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics executives and other stock owners filed with the SEC include: